This Phase 2a proof of concept (PoC) study is a 24-week Induction and Maintenance Period and a 72-week Long-Term Extension Period treat-through design study that utilizes a platform framework. The study will evaluate the clinical efficacy and safety of targeted therapies (TaTs) in moderate to severe CD. For the purpose of this protocol, TaTs represent…
A Phase 3, Randomized, Observer-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age Register Today!
To evaluate the efficacy of MK-7240 compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12. Register Today!
To evaluate the efficacy of MK-7240 compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score at Week 52. Register Today!
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis Register Today!
A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283 compared with mRNA-1273 in participants aged ≥12 years for the prevention of COVID-19. Register Today!
A phase 3 randomized, double-blind, 52-week placebocontrolled multi-center study with a double-blind 52-week extension period with randomized dose up/dose down titration investigating the efficacy, safety, and tolerability of Ritlecitinib in adult participants with nonsegmental vitiligo. Register Today!
A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study. Register Today!
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis For more information, please click here. Register Today!
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Register Today!
